Palisade Bio Provides Update on Stockholders' Meeting
Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, recently faced an unexpected turn of events regarding its special meeting of stockholders. Held at a virtual format, the meeting was convened but adjourned due to a lack of sufficient quorum—a critical threshold necessary for valid decision-making.
Understanding the Quorum Requirement
A quorum for this type of meeting is defined as one-third of the outstanding shares of the Company’s common stock entitled to vote. Unfortunately, only a fraction of stockholders participated, leading to the adjournment. A new meeting has been scheduled for later this month to give stockholders more time to cast their votes on the proposals outlined in the definitive proxy statement.
The Upcoming Meeting Details
The revised special meeting will reconvene at 10:00 a.m. Pacific Time. It aims to engage stockholders who have yet to vote, ensuring their opinions and preferences are effectively represented. The meeting highlights the importance of shareholder engagement, especially when decisions impacting the future of the company are on the table.
Efforts to Increase Stockholder Participation
Palisade Bio has taken several steps to facilitate stockholder participation during this critical time. The company has enlisted Mediant Communications Inc., a proxy solicitor, to assist in reaching out to potential voters. This proactive approach is meant to encourage stockholders to submit their votes ahead of the meeting on September 26.
Voting Instructions for Stockholders
Stockholders of record as of July 28, 2025, who have not yet cast their votes, are strongly encouraged to do so by September 25. The company emphasizes that previous proxies remain valid for the adjourned meeting unless revoked, which simplifies the voting process for many stockholders.
The Implications of Adjournment on Corporate Strategy
If the adjourned meeting does not attract enough votes to reach the quorum, Palisade intends to reconvene again, potentially incurring additional costs. This scenario underlines the challenges that companies like Palisade Bio face in rallying their stockholder base, particularly when critical decisions are pending.
About Palisade Bio
Palisade Bio focuses its efforts on developing innovative therapeutics aimed at treating autoimmune, inflammatory, and fibrotic diseases. The firm is committed to transforming treatment protocols by utilizing targeted therapies that address the underlying causes of these conditions. Such advancements not only hold promise for patients but also enhance the company's position in the biopharmaceutical landscape.
Contact Information for Shareholders
If stockholders have questions or need assistance regarding the voting process, they can reach out to Mediant Communications at 1-888-715-3034 for support. This outreach ensures that all shareholders feel empowered to participate and have their voices heard at this crucial juncture.
Frequently Asked Questions
What was the reason for the adjournment of Palisade Bio's meeting?
The meeting was adjourned due to a lack of sufficient quorum, as not enough stockholders were present to conduct business.
When will the adjourned meeting take place?
The adjourned meeting is scheduled for 10:00 a.m. Pacific Time on September 26.
How can stockholders vote for the proposals?
Stockholders can vote by submitting their votes by September 25, 2025, either in person or by proxy, as outlined in the Proxy Statement.
Who can vote in this meeting?
Only stockholders of record as of July 28, 2025, are entitled to vote at the special meeting.
What happens if there is still no quorum at the next meeting?
If a quorum is not reached again, the special meeting may be adjourned once more, which could lead to additional costs for the Company.
